116.4 33.3 mg/dl; P = 0.013), which resulted significantly higher in sufferers aged 18C65 years than in those aged a lot more than 65 years. In the subgroup of patients aged between 40 and 65 years, both Italian Cuore Score (15.3 11.2 vs. and concomitant medicines. Among treated hypertensive sufferers, we identified just those under one antihypertensive agent (monotherapy). Workplace BP treatment goals were defined regarding to 2018 ESC/ESH suggestions as: (a) 130/80 mmHg in people aged 18C65 Nifedipine years; (b) 140/80 mmHg in those aged 65 years. Outcomes From a standard test of 7797 information we chosen 1578 (20.2%) hypertensive outpatients (47.3% female, age 59.5 13.6 years, BMI 26.6 4.4 kg/m2) treated with monotherapies, among whom 30.5% received ACE inhibitors, 37.7% ARBs, 15.8% beta-blockers, 10.6% CCBs, 3.0% diuretics, and 2.0% alpha-blockers. 36.6% of the patients reached the traditional clinic BP goal of 140/90 mmHg, whilst the 2018 Western european guidelines BP treatment focuses on were fulfilled only in 14.0%. Specifically, 10.2% sufferers aged 18C65 years and 20.4% of these aged 65 years attained the recommended BP goals. Each one of these proportions outcomes significantly less than those attained with dual (18.2%) or triple (22.2%) mixture therapy, though greater than those obtained with life-style adjustments (10.8%). Proportions of sufferers on monotherapies with regular house and 24-h BP amounts had been 22.0% and 30.2%, respectively, though only 5.2% and 7.3% of the patients attained suffered BP control, respectively. Ageing and dyslipidaemia demonstrated significant and indie positive predictive worth for the accomplishment from the suggested BP treatment goals, whereas European SCORE resulted a negative and independent predictor in outpatients treated with monotherapies. Conclusions Our data showed a persistent use of monotherapy in the clinical practice, though with unsatisfactory BP control, especially in light of Nifedipine the BP treatment targets suggested by the last hypertension guidelines. Electronic supplementary material The online version of this article (10.1007/s40292-020-00420-y) contains supplementary material, which is available to authorized users. Student or ANOVA tests, whereas dichotomous variables were tested by Chi square test. Correlations between continuous variables were assessed by Pearson analysis. All tests were two-sided, and a P value of less than 0.05 was considered statistically significant. To evaluate the significance of predictors of the achievement of the recommended BP treatment targets, odds ratios (OR) and 95% confidence intervals (CI) were derived from logistic regression analysis. This analysis was applied Nifedipine only to those patients treated with monotherapies. All calculations were generated using SPSS, version 20.0 for MacOs (SPSS Inc., Chicago, Illinois). Results Study Population From an overall sample of 9010 individuals, we initially identified 7797 adult individuals, among whom we selected 1578 (18.7%) patients (47.3% female, age 59.5 13.6 years, BMI 26.6 4.4 kg/m2) treated with single antihypertensive agent (monotherapy) and valid BP data. In this population, 62.7% patients were aged between 18 and 65 years, and 37.3% were aged more than 65 years. Flow-chart for the selection of the study population is illustrated in Electronic Fig. 1 (online available), while general characteristics of the study population are reported on Table ?Table11. Table 1 General characteristics of the study population of hypertensive outpatients treated with monotherapies body mass index, coronary artery disease, transient ischaemic attack, total cholesterol, Nifedipine high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, blood Nifedipine urea nitrogen *Risk scores were calculated LIFR only in those patients aged between 40 and 65 years Angiotensin receptor blockers (ARBs) were the most commonly used?antihypertensive drugs, accounting for 37.7% of the entire study population, followed by angiotensin converting enzyme (ACE) inhibitors (30.5%), beta-blockers (15.8%), calcium channel blockers (CCBs) (10.6%), diuretics (3.0%), while alpha blockers accounted for a paltry 2.0%. Age distribution of different classes of antihypertensive agents, used in monotherapies, is illustrated in Fig. ?Fig.11. Open in a separate window Fig. 1 Age distribution of different classes of antihypertensive agents used in monotherapies. Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, alpha-blockers. Patients aged 18C65 years showed significantly higher BMI (26.9 4.7 vs. 26.0 3.8; P = 0.004) and higher prevalence of smoking habits (20.9% vs. 11.4%; P 0.001) and obesity (61.9% vs. 55.0%; P = 0.007) than those aged more than 65 years, whereas dyslipidaemia (41.4% vs. 24.9%: P 0.001), diabetes (11.9% vs. 7.3%; P = 0.002), CAD (3.6% vs. 0.6%; P 0.001) and previous stroke or TIA (7.0% vs. 2.8%; P 0.001).